These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 19230021)

  • 21. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies.
    Yang JZ; Young AL; Chiang PC; Thurston A; Pretzer DK
    J Pharm Sci; 2008 Nov; 97(11):4869-78. PubMed ID: 18351635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients.
    Derom E; Van De Velde V; Marissens S; Engelstätter R; Vincken W; Pauwels R
    Pulm Pharmacol Ther; 2005; 18(5):328-36. PubMed ID: 15939311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration.
    Whelan GJ; Blumer JL; Martin RJ; Szefler SJ;
    J Allergy Clin Immunol; 2005 Sep; 116(3):525-30. PubMed ID: 16159619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids.
    Hübner M; Hochhaus G; Derendorf H
    Immunol Allergy Clin North Am; 2005 Aug; 25(3):469-88. PubMed ID: 16054538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children.
    de Blic J; Ogorodova L; Klink R; Sidorenko I; Valiulis A; Hofman J; Bennedbaek O; Anderton S; Attali V; Desfougeres JL; Poterre M
    Pediatr Allergy Immunol; 2009 Dec; 20(8):763-71. PubMed ID: 19239660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations.
    Belda J; Margarit G; Martínez C; Bellido-Casado J; Casan P; Torrejón M; Brufal M; Rodríguez-Jerez F; Sanchis J
    Eur Respir J; 2007 Dec; 30(6):1143-9. PubMed ID: 17690122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
    Allen A; Davis A; Hardes K; Tombs L; Kempsford R
    Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
    Onoue S; Aoki Y; Matsui T; Kojo Y; Misaka S; Mizumoto T; Yamada S
    Int J Pharm; 2011 May; 410(1-2):54-60. PubMed ID: 21419198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic bioavailability of fluticasone in COPD.
    Lipworth BJ; Menzies D
    Am J Respir Crit Care Med; 2005 May; 171(10):1191; author reply 1191-2. PubMed ID: 15879430
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-tissue remodeling effects of corticosteroids: fluticasone propionate inhibits fibronectin expression in fibroblasts.
    Tomic R; Lassiter CC; Ritzenthaler JD; Rivera HN; Roman J
    Chest; 2005 Jan; 127(1):257-65. PubMed ID: 15653993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of fluticasone propionate on acute and chronic inflammation.
    Johnson M
    Int Arch Allergy Immunol; 1995; 107(1-3):441-2. PubMed ID: 7542099
    [No Abstract]   [Full Text] [Related]  

  • 32. Aerosol characterization of nebulized intranasal glucocorticoid formulations.
    Berlinski A; Waldrep JC
    J Aerosol Med; 2001; 14(2):237-44. PubMed ID: 11681655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features.
    Leung SY; Eynott P; Nath P; Chung KF
    J Allergy Clin Immunol; 2005 May; 115(5):989-96. PubMed ID: 15867856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height.
    Visser MJ; Postma DS; Arends LR; de Vries TW; Duiverman EJ; Brand PL
    Am J Respir Crit Care Med; 2001 Dec; 164(11):2073-7. PubMed ID: 11739137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluticasone propionate nanosuspensions for sustained nebulization delivery: An in vitro and in vivo evaluation.
    Fu TT; Cong ZQ; Zhao Y; Chen WY; Liu CY; Zheng Y; Yang FF; Liao YH
    Int J Pharm; 2019 Dec; 572():118839. PubMed ID: 31715359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma.
    Rodrigo GJ
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1231-6. PubMed ID: 15764724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.
    Nials AT; Tralau-Stewart CJ; Gascoigne MH; Ball DI; Ranshaw LE; Knowles RG
    J Pharmacol Exp Ther; 2011 Apr; 337(1):137-44. PubMed ID: 21205924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.
    Salter M; Biggadike K; Matthews JL; West MR; Haase MV; Farrow SN; Uings IJ; Gray DW
    Am J Physiol Lung Cell Mol Physiol; 2007 Sep; 293(3):L660-7. PubMed ID: 17575011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of budesonide and N-acetylcysteine on acute lung hyperinflation, inflammation and injury in rats.
    Jansson AH; Eriksson C; Wang X
    Vascul Pharmacol; 2005 Aug; 43(2):101-11. PubMed ID: 15967733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.
    Weber B; Hochhaus G
    AAPS J; 2015 Jul; 17(4):999-1010. PubMed ID: 25933600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.